

Biomedical Interventions for HIV Prevention Phase 2b & 3 Clinical Trials Details (see Prevention Trial Timeline)

Notes	Full Trial Name	Also known as	Phase	Sponsor(s)	# of people enrolled/expected enrollment	Country(ies)
C1	Trial of Male Circumcision to Reduce HIV Incidence	Male Circumcision and HIV Rates in Kenya	3	University of Illinois, NIH, Canadian Institute of Health Research	2,784 m	Kenya
C2	Trial of Male Circumcision: HIV, STD and Behavioral Effects	Male Circumcision HIV Prevention Rakai Trial	3	Johns Hopkins University, NIH	5,000 m	Uganda
C3	Safety of Male Circumcision in HIV Infected Men and Efficacy in Preventing Transmission to Women		3	JHU, Gates Foundation	1361 m, 7,000 w	Uganda
BM1	The Latex Diaphragm to Prevent HIV Acquisition Among Women: A Female-Controlled, Physical Barrier of the Cervix	Diaphragm & Replens Gel	3	University of California at San Francisco, Gates Foundation	5,045 w	South Africa and Zimbabwe
M1	Phase 3 Study of Efficacy and Safety of the Microbicide Carraguard in Preventing Seroconversion in Women	Carraguard	3	Population Council, Gates Foundation, USAID	6639 w	South Africa
M2	Phase 2/2B safety and effectiveness study of two vaginal microbicides BufferGel and 0.5% PRO 2000/5 Gel (P) for the prevention of HIV infection in women (HPTN 035)	MTN 035	2/2B	NIH-NIAID, Indevus, ReProtect	3100 w	Malawi, South Africa, USA, Zambia, Zimbabwe, Nigeria
M3	An international, multi-center randomised, double-blind, placebo-controlled trial to evaluate the efficacy and safety of 0.5% and 2% PRO 2000/5 gels for the prevention of vaginally acquired HIV infection	Pro-2000/5	3	Indevus, MRC, DFID	9673 w	South Africa, Tanzania, Uganda, Zambia
M4	Randomized Controlled Trial of 6% CS Gel and the Effect on Vaginal HIV Transmission	Cellulose sulfate gel	3	CONRAD, USAID, Gates Foundation	2574 w	Uganda, Zimbabwe, India, South Africa, Benin
M5	Randomized Controlled Trial of Cellulose Sulfate Gel and HIV in Nigeria	Cellulose sulfate gel	3	Family Health International, USAID, CONRAD	2160 w	Nigeria
H1	A Phase 3, randomized, double-blind, placebo-controlled trial of acyclovir for the reduction of HIV acquisition among high risk HSV-2 seropositive, HIV-seronegative individuals	HPTN 039	3	University of Washington, NIH	3277 m and w	Peru, South Africa, Zambia, Zimbabwe, USA
H2	Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression	Partners in Prevention	3	University of Washington, Gates Foundation	3,000 discordant heterosexual couples	Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, Zambia
P1	Study of the Safety and Efficacy of Daily Tenofovir to Prevent HIV Infection	Thailand/TDF	3	CDC	2000 IDU	Thailand
P2	Study of the Safety and Efficacy of Daily Tenofovir Disoproxil Fumarate (TDF) among HIV-1 Negative Men	Botswana TDF + Emt	3	CDC	1200 m and w	Botswana
P3	Chemoprophylaxis for HIV Prevention in Men	Andean PREP Trail	3	NIH	1400 MSM (proposal to increase to 2700)	Peru, Ecuador
P4	Phase 2 Extended Safety Study of Tenofovir-Disoproxil Fumarate (TDF) among HIV-1 Negative Men		2	CDC	400 MSM	US A
IP1	A Randomized trial to Evaluate the Effectiveness of Antiretroviral Therapy plus HIV Primary Care versus HIV Primary Care Alone to Prevent the Sexual Transmission of HIV-1 in Serodiscordant Couples	HPTN 052	3	NIH, GSK, Boehringer-Ingelheim	1750 serodiscordant couples	Malawi, India, Zimbabwe, Brazil, Thailand, USA
V1	The purpose of the Merck/HVTN proof of concept trial is to obtain information about the safety of the MRKAd5 HIV-1 gag/pol/nef, or trivalent, vaccine in humans and to learn if it can prevent HIV infection	HVTN 502/ Merck 0123 Step Study	2B	Merck & Co., NIH, HVTN	3000 m and w	Australia, Brazil, Canada, Dominican Republic, Haiti, Jamaica, Peru, Puerto Rico, USA
V2	A Multicenter Double-Blind Randomized Placebo-Controlled Trial of the Safety and Efficacy of the MRKAd5 HIV-1 gag/pol/nef, or trivalent, vaccine in humans and to learn if it can prevent HIV infection	HVTN503	2B	Merck Research Laboratories, NIH, HVTN, SAAVI	3000 m and w	South Africa
V3	A Phase III Trial of Aventis Pasteur Live Recombinant ALVAC HIV-1 Vaccine	Alvac + AIDSVAX	3	Thailand Ministry of Public Health, Thai AIDS Vaccine Evaluation Group, Armed Forces Research Institute of Medical Sciences	16,402 m and w	Thailand